Abstract

Relevance. Perioral dermatitis is a common dermatosis that predominantly affects women aged 25-40 but is also observed in children and adolescents. The distinct localization of this condition in the perioral, perinasal, and periocular zones contributes to apparent psycho-emotional distress, markedly impairing patients' quality of life. Perturbations in the skin biotope, local immune dysregulation, and topical glucocorticosteroid use are among the primary etiological factors. Effective management involves addressing causative factors, discontinuation of topical steroids, adopting gentle skincare practices, and employing localized treatments like metronidazole, pimcrolimus, and activated zinc pyrithione. Maintenance therapy may be warranted in select cases. The purpose of this work is to review the current literature on the problem and to present original clinical observations concerning the utilization of activated zinc pyrithione in treating patients with this condition. Materials and methods. The article presents the results of the use of topical zinc pyrithione in patients spanning various age groups and exhibiting diverse degrees of perioral dermatitis severity. Discussion. Significant clinical evidence substantiates the remarkable efficacy and safety profile of activated zinc pyrithione in managing perioral dermatitis, both as a standalone therapeutic modality and as an integral component of combination therapy. Conclusions. The use of activated zinc pyrithione in the treatment of perioral dermatitis emerges as an efficacious and secure approach for treating mild to moderate forms of the condition. Keywords: orofacial dermatitis, skin microbiome, chronic inflammation, age periods, Demodex, Malassezia spp., S.aureus, activated zinc pyrithione

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call